Explain this page
Arphra AIPlain-English read on Boston Scientific Corporation’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.63% | -2.13% | -15.61% | -35.44% | -51.63% | -49.99% | -53.75% | -7.24% | +15.31% | +109.12% | +1013.69% |
Aftermarket
LiveLast trade
$48.00
378 sh
Bid
$47.64
1 sh
Ask
$47.98
60 sh
Spread
$0.340
Sector & industry today
LiveSectors
- Technology+1.59%
- Industrials+1.50%
- Energy+1.40%
- Basic Materials+1.36%
- Utilities+0.94%
- Consumer Cyclical+0.45%
- Real Estate+0.37%
- Consumer Defensive+0.28%
- Financial Services+0.05%
- Healthcare-0.26%
- Communication Services-0.39%
Top industries (issuer's industry highlighted)
- Medical - Devices-0.37%
- Hardware, Equipment & Parts+5.17%
- Computer Hardware-4.64%
- REIT - Office+4.28%
- Communication Equipment+4.02%
- Electronic Gaming & Multimedia-3.94%
- Real Estate - Services+3.82%
- Agricultural - Machinery+3.64%
- Auto - Parts+3.58%
- Oil & Gas Energy+3.45%
- Information Technology Services+3.19%
- Copper+3.00%
Fair value
Football field →Weighted blend
$369.48
+674.92% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
5bull8bear
±5% threshold
Analyst PT consensus: $91.33 (+91.55%)
Total assets
$43.67B
Total debt
$12.42B
Cash & equiv
$2.05B
Operating CF
$4.53B
Free cash flow
$3.66B
Buybacks
$0
Analyst view
DB · price_targets + analyst_gradesConsensus target
$91.33
+91.55% upside
Low
$60.00
Median
$90.00
High
$120.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- BSX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026businesswire.com·May 04, 2026
- BSX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026businesswire.com·May 04, 2026
- BSX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSXnewsfilecorp.com·May 04, 2026
- BSX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSXnewsfilecorp.com·May 04, 2026
- Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 resultsprnewswire.com·May 04, 2026
- Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 resultsprnewswire.com·May 04, 2026
- BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSXglobenewswire.com·May 03, 2026
- BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSXglobenewswire.com·May 03, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $5.2B | $1.34B | $0.90 |
| Q4 Dec 2025 | $5.29B | $668M | $0.45 |
| Q3 Sep 2025 | $5.07B | $755M | $0.50 |
| Q2 Jun 2025 | $5.06B | $793M | $0.53 |
| Q1 Mar 2025 | $4.66B | $674M | $0.45 |
| Q4 Dec 2024 | $4.56B | $566M | $0.38 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Mahoney Michael F director, officer: Chairman, President & CEO | Sell | 1,200 | $112.87K | Feb 02, 2026 |
Mahoney Michael F director, officer: Chairman, President & CEO | Sell | 159,701 | $14.93M | Feb 02, 2026 |
Butcher Arthur C officer: EVP& Grp Pres, MedSurg & APAC | Sell | 17,313 | $1.76M | Dec 01, 2025 |
Zane Ellen M director | Sell | 12,891 | $1.27M | Nov 06, 2025 |
Fitzgerald Joseph Michael officer: EVP & Group Pres, Cardiology | Sell | 3,600 | $362.69K | Nov 03, 2025 |
Fitzgerald Joseph Michael officer: EVP & Group Pres, Cardiology | Sell | 16,928 | $1.69M | Nov 03, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $20.07B | $3.97B | $2.89B | $1.94 | +14.38% |
| FY 2024 | $16.75B | $2.64B | $1.85B | $1.25 | +11.07% |
| FY 2023 | $14.24B | $2.18B | $1.59B | $1.07 | +11.19% |
| FY 2022 | $12.68B | $1.82B | $698M | $0.45 | +5.50% |
| FY 2021 | $11.89B | $1.92B | $1.04B | $0.69 | +8.75% |